PathAI
Digital pathology image management and AI applications

PathAI develops AISight digital pathology software and AI applications for laboratories and biopharma, with separate clinical-diagnostic and research tools.
Best for
- Pathology laboratories modernizing digital slide review and case management
- Laboratories and biopharma teams that can evaluate each AI application’s intended use separately
Not ideal for
- Buyers treating every AISight research application as cleared cancer-detection software
- Laboratories without a validated scanning and diagnostic workflow

Bottom line
PathAI is a strong option for laboratories seeking digital pathology workflow software with access to AI applications. It is most useful when clinical image management, research tools, and cancer-specific algorithms are evaluated as distinct components.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
PathAI serves pathology laboratories moving from physical slides to digital review, as well as biopharma teams using tissue images in research. Ibex Medical is a relevant alternative when the purchase concerns cancer-AI assistance. It is a narrower comparison than replacing the entire image-management environment, and the exact algorithm, cancer indication, and geography matter.
This is an enterprise laboratory purchase involving software, scanning infrastructure, integration, and validation. Roche announced its agreement to acquire PathAI in May 2026, and a November 4 Roche page describes the combined offering as active. PathAI and AISight continue as identifiable technology brands within that offering.
- Outcomes and workflow value (8.0): Clinical IMS clearance and active laboratory deployments support workflow value, without establishing a universal cancer-AI accuracy claim.
- Product and service depth (8.5): Case management, whole-slide review, collaboration, and AI applications form a substantial pathology offering.
- Ease of implementation (6.7): Scanner configuration, validation, laboratory integration, and module-specific regulatory checks make implementation demanding.
- Pricing clarity (6.0): Enterprise software and service pricing is negotiated, with no current public rate card for the clinical offering.
AISight and AISight Dx Have Different Uses
AISight is an image-management and research platform. Roche’s November page explicitly labels AISight for research use only and not for diagnostic procedures. AISight Dx is the clinical image-management system, FDA-cleared for primary diagnosis in the US and CE-IVD-marked for primary diagnosis in the EEA, Switzerland, and the UK.
The current PathAI clinical product page describes case routing, slide review, annotation, and consult collaboration. It lists the Leica Aperio GT 450 DX, Hamamatsu NanoZoomer S360MD, and Roche VENTANA DP200 and DP600 scanners. A laboratory should validate the current authorized configuration for its own jurisdiction and workflow.
Cancer AI Requires a Module-Level Comparison
Image-management clearance permits specified diagnostic slide-review workflows. It does not establish that every AI algorithm available on the platform is authorized to detect every cancer. Research biomarkers, trial endpoints, diagnostic assistance, and companion diagnostics have different intended uses.
A comparison with Ibex should therefore identify the specific cancer application, specimen, indication, algorithm version, supporting validation, and local authorization. A research AI menu can be valuable to a biopharma team while remaining unsuitable for routine patient diagnosis. No platform-wide sensitivity or specificity figure can resolve those distinctions.
Laboratory Workflow and the Roche Combination
AISight Dx brings cases, digital slides, review, and collaboration into one environment. Those capabilities can reduce the movement of physical materials and make consultations easier across sites. Their practical usefulness depends on image quality, network performance, workload routing, and connection to the laboratory’s existing systems.
Roche’s November account emphasizes an open IMS and compatibility with other developers’ scanners and algorithms. That is useful direction for a laboratory protecting its existing investments. Procurement still needs a written inventory of supported interfaces and modules, as well as service responsibilities during the organizational transition.
Product and service details: pathai.com, diagnostics.roche.com.
Company scale
Similarweb’s September 2026 profile estimates PathAI annual revenue at $25 million to $50 million. Scale source
What People Say
What people like
"Having the case list, slide review, and consultations in one place would simplify our digital pathology work."
"An open image-management system would help us preserve choices about scanners and AI applications."
What people don't like
"We cannot use a research algorithm for diagnosis just because it appears in the same software environment."
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation.
Based on: Product or service details, Product or service details.
The scored comparison is limited to overlapping clinical cancer-AI evaluation. Platform-wide IMS functions and research applications require separate comparison.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| PathAI | 7.6 | 6.7 |
| Ibex Medical Analytics | 7.5 | 6.8 |
Pricing
| Item | Detail |
|---|---|
| Clinical deployment | Negotiated enterprise software and services; no public dollar rate. |
| Required scope | Specify IMS, AI modules, scanners, laboratory interfaces, storage, validation, training, and support. |
| Research services | Biopharma research applications and clinical-trial services are separate from routine diagnostic use. |
Recent news
- November 2026: Roche Diagnostics described the combined Roche and PathAI digital pathology offering, with the AISight image management system continuing as its platform.
- May 2026: Roche announced a definitive agreement to acquire PathAI.
Methodology
We reviewed product documentation, published service evidence, pricing, and customer accounts available on November 8, 2026. Scores are editorial assessments on a ten-point scale. The overall score weights outcomes and workflow value at 35%, product at 30%, implementation at 20%, and pricing clarity at 15%. Company-website testimonials are vendor-selected accounts.
Existing peer scores are carried from the linked HIR reviews.
Sources
- Healthcare Industry Reviews analysis of the product, service, and pricing sources below, conducted November 2026.
- pathai.com · aisightdx digital pathology solution
- diagnostics.roche.com · global/en/diagnostics insights/pathai roche digital pathology.html
- similarweb.com · company/pathai.com
- roche.com · media/releases/med cor 2026 05 07
- pathai.com · news/pathai receives fda clearance for aisight dx platform for primary diagnosis